The global pharmaceutical and bio industry is currently in an 'AI transition period.' Major companies worldwide are rapidly adopting artificial intelligence (AI) to increase the speed of new drug development, improve clinical success rates, and maximize production efficiency. AI, which analyzes vast amounts of medical data to enable disease prediction and personalized treatment, has established itself as a key growth driver in the future healthcare industry.

GC Group is also accelerating innovation by applying AI across all company operations, including diagnosis, examination, research and development, quality control, and manufacturing, with GC Green Cross and its affiliates at the forefront. Beyond the simple adoption stage, each affiliate is advancing AI in specialized areas to enhance global competitiveness.

GC Care and GC Genome, Opening Personalized Diagnosis and Examination with AI

GC Care, which provides personalized healthcare services, integrates AI into its health management app 'OttoCare' to help quickly and accurately assess health conditions. The recently introduced 'AI Examination Report' simplifies complex figures and suggests improvement points to support personalized health management. AI also analyzes results from precision tests such as gastroscopy and ultrasound, predicting the likelihood of 19 major diseases, including hypertension and diabetes, enabling preventive management.

Changes are also evident in the diagnostic field. GC Genome, an affiliate specializing in liquid biopsy and clinical genome analysis, has applied an AI-based proprietary algorithm to its flagship product, the multi-cancer early detection test 'ai-CANCERCH.' The core technology, 'FEMS (Fragment End Motif by Size),' simultaneously analyzes the fragment size and sequence pattern of cell-free DNA (cfDNA) to detect early cancer signals that are difficult to capture with existing tests.

Ubicare, Innovating Medical Environment and Efficiency with AI

AI plays a role in improving the efficiency of medical treatment by utilizing diagnostic and examination data from patients. Ubicare, which operates the EMR (Electronic Medical Record) solution 'Doctor's Love,' uses 'Doctor's Love AI Clinic' to automatically record and summarize patient consultations and analyze two years of medical data to help doctors quickly understand the patient's condition.

In this process, AI provides personalized treatment guides, recommends prescription codes, and alerts about contraindications or risk of reduction drugs. Furthermore, it offers lifestyle education materials, enhancing the quality of medical treatment. Recently, in collaboration with Samsung Electronics, it has connected IoT devices in the clinic, allowing real-time monitoring of patient health data, leading to innovations in the medical environment.

GC Green Cross, Accelerating New Drug Development, Quality, and Manufacturing Innovation

Data accumulated from patient diagnosis and medical sites is leading to research and development and production innovation. GC Green Cross has applied AI-based codon optimization technology to its proprietary mRNA/LNP platform to enhance the efficiency of candidate substances and confirmed efficacy and safety in rare disease models. This contributes to accelerating new drug development and increasing the likelihood of success.

The pipeline being developed most rapidly using AI-based codon optimization technology is the COVID-19 mRNA vaccine. GC Green Cross is accelerating development with the goal of obtaining IND approval for Phase 1 clinical trials within the year. As the AI-discovered candidate substance has demonstrated similar levels of immunogenicity and protective ability to existing commercialized products in the preclinical stage, the development potential has significantly increased. GC Green Cross analyzes that once the AI-based mRNA/LNP platform is verified through clinical trials, it will be possible to respond within 100 days in the event of a new pandemic.

In the field of quality control, GC Green Cross is leading changes by utilizing AI. The introduction of an AI-based document automation system has reduced the time required to prepare annual evaluation reports by more than 80%, and collaboration with AWS and Megazone Cloud has established a real-time data analysis system. In the manufacturing sector, generative AI is being used to promote regulatory inspection simulations and process optimization, becoming a key driver of the 'Pharma 4.0' strategy. It is simultaneously achieving quality improvement and maximizing production efficiency. A GC Group official stated, "AI is no longer a choice but a necessity," and added, "We will strengthen global competitiveness through AI innovation across the entire healthcare sector, from diagnosis to production."

Popular News